FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033461855> ?p ?o ?g. }

• W2033461855 endingPage "1575" @default.
• W2033461855 startingPage "1567" @default.
• W2033461855 abstract "It is widely accepted that most cell types efficiently exclude oligonucleotides in vitro and require specific delivery systems, such as cationic lipids, to enhance uptake and subsequent antisense effects. Oligonucleotides are not readily transfected into leukaemia cell lines using cationic lipid systems and streptolysin O (SLO) is used to effect their delivery. We wished to investigate the optimal oligonucleotide composition for antisense efficacy and specificity following delivery into leukaemia cells using SLO. For this study the well characterised chronic myeloid leukaemia cell line KYO-1 was selected and oligonucleotides (20mers) were targeted to an empirically identified accessible site of c-myc mRNA. The efficiency and specificity of antisense effect was measured 4 and 24 h after SLO-mediated delivery of the oligonucleotides. C5-propyne phosphodiester and phosphorothioate compounds were found to present substantial non-specific effects at 20 µM but were inactive at 0.2 µM. Indeed, no antisense-specific effect was noted at any concentration at either time. All of the other oligonucleotides tested induced some measurable antisense effect, except 7 (chimeric, all-phosphorothioate, 2′-methoxyethoxy termini) which was essentially inactive at 20 µM. The rank efficiency order of the remaining antisense compounds was 4 = 3 ≫ 9 ≫ 10 = 8 = 5 = 6 > 11. The efficient antisense effects induced by the chimeric methylphosphonate-phosphodiester compounds were found to be highly specific. Increased phosphorothioate content in the oligonucleotide backbone correlated with reduced antisense activity (efficacy: 2′-methoxyethoxy series 9 ≫ 8 ≫ 7, 2′-methoxytriethoxy series 10 > 11). No consistent evidence was obtained for increased activity correlating with increased oligonucleotide-mRNA heteroduplex thermal stability. In conclusion, the chimeric methylphosphonate-phosphodiester oligodeoxynucleotides present the most favourable characteristics of the compounds tested, for efficient and specific antisense suppression of gene expression following SLO-mediated delivery." @default.
• W2033461855 created "2016-06-24" @default.
• W2033461855 creator A5010285060 @default.
• W2033461855 creator A5011733008 @default.
• W2033461855 creator A5020913751 @default.
• W2033461855 creator A5025297677 @default.
• W2033461855 creator A5040757424 @default.
• W2033461855 creator A5067522555 @default.
• W2033461855 date "1998-04-01" @default.
• W2033461855 modified "2023-10-11" @default.
• W2033461855 title "Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells" @default.
• W2033461855 cites W1495194877 @default.
• W2033461855 cites W1508773001 @default.
• W2033461855 cites W1564730852 @default.
• W2033461855 cites W1733933634 @default.
• W2033461855 cites W1774527113 @default.
• W2033461855 cites W1906502852 @default.
• W2033461855 cites W1967114346 @default.
• W2033461855 cites W1969818257 @default.
• W2033461855 cites W1970605675 @default.
• W2033461855 cites W1976545417 @default.
• W2033461855 cites W1981481692 @default.
• W2033461855 cites W1982792956 @default.
• W2033461855 cites W1984718218 @default.
• W2033461855 cites W1988408638 @default.
• W2033461855 cites W1998919839 @default.
• W2033461855 cites W2010655741 @default.
• W2033461855 cites W2012851022 @default.
• W2033461855 cites W2014846266 @default.
• W2033461855 cites W2020092689 @default.
• W2033461855 cites W2038588592 @default.
• W2033461855 cites W2050230983 @default.
• W2033461855 cites W2051010056 @default.
• W2033461855 cites W2061791707 @default.
• W2033461855 cites W2065176243 @default.
• W2033461855 cites W2066537745 @default.
• W2033461855 cites W2068230814 @default.
• W2033461855 cites W2077947305 @default.
• W2033461855 cites W2081638226 @default.
• W2033461855 cites W2083091935 @default.
• W2033461855 cites W2090183104 @default.
• W2033461855 cites W2090553360 @default.
• W2033461855 cites W2092679887 @default.
• W2033461855 cites W2094926987 @default.
• W2033461855 cites W2097699954 @default.
• W2033461855 cites W2115524556 @default.
• W2033461855 cites W2133446679 @default.
• W2033461855 cites W2134812217 @default.
• W2033461855 cites W2135050886 @default.
• W2033461855 cites W2140505271 @default.
• W2033461855 cites W2148320915 @default.
• W2033461855 cites W2155463132 @default.
• W2033461855 cites W2162258100 @default.
• W2033461855 cites W2261530410 @default.
• W2033461855 cites W2320948705 @default.
• W2033461855 cites W2402187618 @default.
• W2033461855 cites W2409795005 @default.
• W2033461855 cites W2410014644 @default.
• W2033461855 cites W2413736157 @default.
• W2033461855 cites W2415007543 @default.
• W2033461855 cites W2415881972 @default.
• W2033461855 cites W2419486489 @default.
• W2033461855 cites W2426280944 @default.
• W2033461855 cites W2433949023 @default.
• W2033461855 cites W4294216491 @default.
• W2033461855 doi "https://doi.org/10.1093/nar/26.7.1567" @default.
• W2033461855 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/147466" @default.
• W2033461855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9512525" @default.
• W2033461855 hasPublicationYear "1998" @default.
• W2033461855 type Work @default.
• W2033461855 sameAs 2033461855 @default.
• W2033461855 citedByCount "79" @default.
• W2033461855 countsByYear W20334618552012 @default.
• W2033461855 countsByYear W20334618552013 @default.
• W2033461855 countsByYear W20334618552015 @default.
• W2033461855 countsByYear W20334618552016 @default.
• W2033461855 countsByYear W20334618552018 @default.
• W2033461855 countsByYear W20334618552019 @default.
• W2033461855 countsByYear W20334618552021 @default.
• W2033461855 countsByYear W20334618552023 @default.
• W2033461855 crossrefType "journal-article" @default.
• W2033461855 hasAuthorship W2033461855A5010285060 @default.
• W2033461855 hasAuthorship W2033461855A5011733008 @default.
• W2033461855 hasAuthorship W2033461855A5020913751 @default.
• W2033461855 hasAuthorship W2033461855A5025297677 @default.
• W2033461855 hasAuthorship W2033461855A5040757424 @default.
• W2033461855 hasAuthorship W2033461855A5067522555 @default.
• W2033461855 hasBestOaLocation W20334618552 @default.
• W2033461855 hasConcept C104317684 @default.
• W2033461855 hasConcept C129312508 @default.
• W2033461855 hasConcept C14363569 @default.
• W2033461855 hasConcept C153911025 @default.
• W2033461855 hasConcept C155887181 @default.
• W2033461855 hasConcept C202751555 @default.
• W2033461855 hasConcept C2776993315 @default.
• W2033461855 hasConcept C2908938912 @default.
• W2033461855 hasConcept C2993175405 @default.
• W2033461855 hasConcept C38441620 @default.

• next